Who founded Regenx Biosciences?

Regenx Biosciences was founded by Kenneth T. Mills.

Who are Regenx Biosciences's investors?

Regenx Biosciences's investors include F-Prime Capital, HEALTHCARE ROYALTY PARTNERS, Venrock.

How much funding has Regenx Biosciences raised?

Regenx Biosciences has disclosed $98M raised across 2 rounds.

Where is Regenx Biosciences headquartered?

Regenx Biosciences is headquartered in Rockville, US.

Regenx Biosciences

Rockville, US · 3 known investors

REGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.

Biotech Healthtech

Founders & leadership

Kenneth T. MillsFounder

Board

John Daniel KiserBoard director

Allan M. FoxBoard director

Benjamin AuspitzBoard director

Donald J. Hayden, Jr.Board director

Investors · 3

F-Prime CapitalCambridge · $3M – $10M

HEALTHCARE ROYALTY PARTNERSNew York

VenrockPalo Alto · $500K – $10M

Reported raises · per SEC filings

Form D private placements

$98M disclosed across 2 rounds · 2015

▶$70.5MraisedMay 2015 · 36 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Allan M. FoxDirector
Luke BesharDirector
Camille SamuelsDirector
Kenneth T. MillsExecutive Officer, Director
Benjamin AuspitzDirector
Donald J. Hayden, Jr.Director

Offering amount: $70.5M
Amount sold: $70.5M
Sales commissions: $2.3M
Placement agents: Chardan Capital Markets, LLC
First sale: May 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$27.5MraisedJan 2015 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kenneth T. MillsExecutive Officer, Director
John Daniel KiserDirector
Allan M. FoxDirector
Benjamin AuspitzDirector
Donald J. Hayden, Jr.Director

Offering amount: $30M
Amount sold: $27.5M
First sale: Jan 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Seeking Alpha63 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Companies competing with Regenx Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Regenx Biosciences do?: REGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.
Who founded Regenx Biosciences?: Regenx Biosciences was founded by Kenneth T. Mills.
Who are Regenx Biosciences's investors?: Regenx Biosciences's investors include F-Prime Capital, HEALTHCARE ROYALTY PARTNERS, Venrock.
How much funding has Regenx Biosciences raised?: Regenx Biosciences has disclosed $98M raised across 2 rounds.
Where is Regenx Biosciences headquartered?: Regenx Biosciences is headquartered in Rockville, US.